PMC10475224_01
(a) Clinical course of the neurological immune-related adverse event and steroid treatment. (b) Serial chest CT scan. (i) CT performed before chemoimmunotherapy administration revealed the presence of a tumor on the upper lobe of the left lung (arrow) and liver metastasis over right lobe of liver (black arrow). (ii) CT performed after three cycles of chemoimmunotherapy indicated almost complete remission without a residual tumor. (iii) Latest CT performed at follow-up, approximately 24 months after the neurological immune-related adverse event, indicated no disease progression. (c) Serial brain MRI. (i) Brain MRI performed before chemoimmunotherapy administration revealed no metastatic lesions. (ii) MRI performed few days after progressive ataxia. (iii and iv) MRI performed three and 24 months after the event showed slight cerebellum atrophy, as evident from the widened cerebrospinal fluid space (arrowhead).. CT, computed tomography; MRI, magnetic resonance imaging.
10.1177_17588359231192398-fig1.jpg
PMC10475224_01_10.1177_17588359231192398-fig1.jpg
fig1-17588359231192398
Chest computed tomography (CT) indicated almost complete resolution of the previous lung tumor, mediastinal lymphadenopathy [Figure 1(b)]. Emergent brain MRI revealed no intracranial lesions [Figure 1(c)]. Subsequently, pulse therapy was started with methylprednisolone at a dose of 1000 mg/day for 5 days, followed by oral prednisolone at a dose of 80 mg/day for 2 weeks, with gradual tapering [Figure 1(a)].